- Home
- GORV vs INKT Comparison
GORV vs INKT Comparison
Compare GORV & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- INKT
- Stock Information
- Founded
- GORV 1976
- INKT 2017
- Country
- GORV United States
- INKT United States
- Employees
- GORV N/A
- INKT N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- INKT Medicinal Chemicals and Botanical Products
- Sector
- GORV Consumer Discretionary
- INKT Health Care
- Exchange
- GORV Nasdaq
- INKT Nasdaq
- Market Cap
- GORV 25.3M
- INKT 28.8M
- IPO Year
- GORV 2015
- INKT 2021
- Fundamental
- Price
- GORV $7.14
- INKT $28.86
- Analyst Decision
- GORV Hold
- INKT Hold
- Analyst Count
- GORV 2
- INKT 3
- Target Price
- GORV $2.00
- INKT $37.50
- AVG Volume (30 Days)
- GORV 80.2K
- INKT 2.7M
- Earning Date
- GORV 08-15-2025
- INKT 08-12-2025
- Dividend Yield
- GORV N/A
- INKT N/A
- EPS Growth
- GORV N/A
- INKT N/A
- EPS
- GORV N/A
- INKT N/A
- Revenue
- GORV $767,257,000.00
- INKT N/A
- Revenue This Year
- GORV $15.65
- INKT N/A
- Revenue Next Year
- GORV $20.54
- INKT N/A
- P/E Ratio
- GORV N/A
- INKT N/A
- Revenue Growth
- GORV N/A
- INKT N/A
- 52 Week Low
- GORV $3.95
- INKT $4.56
- 52 Week High
- GORV $106.80
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- GORV 51.39
- INKT 60.80
- Support Level
- GORV $6.49
- INKT $6.80
- Resistance Level
- GORV $8.01
- INKT $76.00
- Average True Range (ATR)
- GORV 0.74
- INKT 5.95
- MACD
- GORV 0.04
- INKT 3.73
- Stochastic Oscillator
- GORV 61.32
- INKT 35.31
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.